Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study

BACKGROUND: The FLAME study compared once-daily indacaterol/glycopyrronium (IND/GLY) 110/50 μg with twice-daily salmeterol/fluticasone (SFC) 50/500 μg in symptomatic patients with moderate to very severe COPD and a history of exacerbations in the previous year. METHODS: This prespecified and post ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogelmeier, Claus F, Chapman, Kenneth R, Miravitlles, Marc, Roche, Nicolas, Vestbo, Jørgen, Thach, Chau, Banerji, Donald, Fogel, Robert, Patalano, Francesco, Olsson, Petter, Kostikas, Konstantinos, Wedzicha, Jadwiga A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901128/
https://www.ncbi.nlm.nih.gov/pubmed/29692607
http://dx.doi.org/10.2147/COPD.S160011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901128/
https://www.ncbi.nlm.nih.gov/pubmed/29692607
http://dx.doi.org/10.2147/COPD.S160011

Ejemplares similares